David Socks

David Socks is a Venture Partner with Frazier Healthcare Partners, where he focuses on company creation. In this capacity, he co-founded Outpost Medicine, Passage Bio, Recida Therapeutics and Scout Bio. Mr. Socks was Chief Executive Officer of Outpost and Scout, and he currently serves as Executive Chairman of Recida and as a Board member of Outpost.

Prior to joining Frazier, he co-founded Incline Therapeutics and served as the company’s President and Chief Operating Officer until its sale to The Medicines Company for up to $390 million. Previously, he was a Venture Partner at Windamere Venture Partners, where he co-founded companies including Cadence (acquired by Mallinckrodt for $1.3 billion), Somaxon Pharmaceuticals (acquired by Pernix Therapeutics) and Verus Pharmaceuticals (acquired by AstraZeneca and Shionogi/Sciele). At Cadence, Mr. Socks served as Senior Vice President of corporate development and strategy. He has also worked in private equity and management consulting.

Mr. Socks holds a B.S. from Georgetown University and an M.B.A. from Stanford University.